Nuvation Bio Inc. (NUVB): Cash & Equivalents
$164.09M
As of 2025-12-31
$258.60M
As of 2026-06-30
+17.5%
3-year compound annual growth
+40.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $164.09M | +359.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $35.72M | -16.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $42.65M | -57.8% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $101.10M | -23.7% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $132.42M | +345.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $29.75M | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Journey Medical Corp (DERM) | 2025-12-31 | $24.09M | +18.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $26.31M | -15.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
Compare NUVB, FBIO, TNGX, DERM side by side · Screen every company in Pharmaceutical Preparations ↗